Perspective Therapeutics (NYSE:CATX) Earns “Outperform” Rating from Wedbush

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a note issued to investors on Monday,RTT News reports. They currently have a $11.00 target price on the stock. Wedbush’s price target indicates a potential upside of 243.75% from the stock’s previous close.

A number of other research analysts also recently weighed in on the stock. Royal Bank of Canada reduced their target price on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a research report on Monday, November 25th. Oppenheimer reduced their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the company from $24.00 to $5.00 in a research note on Monday, November 25th. Truist Financial started coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 price target for the company. Finally, UBS Group began coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.14.

Perspective Therapeutics Trading Down 5.9 %

Shares of Perspective Therapeutics stock opened at $3.20 on Monday. The business’s fifty day simple moving average is $4.80 and its 200 day simple moving average is $10.15. Perspective Therapeutics has a 12 month low of $2.70 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting analysts’ consensus estimates of ($0.21). The company had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. On average, sell-side analysts predict that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Insider Activity

In other Perspective Therapeutics news, CEO Johan M. Spoor bought 8,000 shares of Perspective Therapeutics stock in a transaction that occurred on Wednesday, December 4th. The stock was acquired at an average cost of $3.77 per share, for a total transaction of $30,160.00. Following the completion of the transaction, the chief executive officer now directly owns 36,257 shares in the company, valued at $136,688.89. This represents a 28.31 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Heidi Henson purchased 25,975 shares of the stock in a transaction on Wednesday, December 4th. The stock was acquired at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the acquisition, the director now owns 25,975 shares in the company, valued at approximately $100,003.75. This represents a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 67,570 shares of company stock worth $256,789 over the last ninety days. Company insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its position in Perspective Therapeutics by 214.0% during the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock valued at $1,369,000 after purchasing an additional 93,548 shares during the last quarter. Rhumbline Advisers bought a new stake in shares of Perspective Therapeutics during the 2nd quarter worth $630,000. Victory Capital Management Inc. purchased a new position in Perspective Therapeutics in the second quarter worth $117,000. WINTON GROUP Ltd bought a new position in Perspective Therapeutics in the second quarter valued at $841,000. Finally, WealthPLAN Partners LLC purchased a new stake in Perspective Therapeutics during the second quarter valued at about $1,695,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.